Triple-Receptor Signaling
Studied for agonist activity at the GIP, GLP-1, and glucagon receptors within a single peptide molecule.
Overview
SRX-31 (RT) is a single-molecule peptide studied for its interaction with three distinct metabolic pathways: the GIP, GLP-1, and glucagon receptors. Where earlier generations of incretin-based compounds engaged one or two of these receptors, SRX-31 (RT) was designed to address all three within a single sequence, making it one of the most closely followed compounds in current metabolic research.
Suria's SRX-31 (RT) is offered for laboratory research, with batch-specific analytical documentation made available through Suria's Batch Documentation system for applicable tested batches.
Research Use Only. Not for human or veterinary use.
Specifications
Certificate of Analysis
Certificate of Analysis
Checking certificate…
Other documentation: Batch Documentation.
Research Highlights
Studied for agonist activity at the GIP, GLP-1, and glucagon receptors within a single peptide molecule.
Investigated in experimental and clinical research examining the combined signaling effects of GIP, GLP-1, and glucagon receptor activation.
A prominent investigational example of a unimolecular GIP, GLP-1, and glucagon receptor agonist.
Engineered as a long-acting peptide for study of sustained triple-receptor agonism in controlled research settings.
Storage
Store at −20°C, protected from light and moisture, until ready for reconstitution.
Store at 2–8°C and use within the laboratory's established handling window.
Avoid repeated freeze-thaw cycles to help preserve peptide integrity across a research protocol.
Research Use Only. Not for human consumption.
Frequently Asked Questions
Batch Documentation